Mylan has launched the first biosimilar to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the name Sirdupla in the UK. Sirdupla is a pressurized metered-dose inhaler (pMDI) indicated to treat symptoms of asthma. 3M Drug Delivery Systems will manufacture the product, which is available in 125/25 mcg and 250/25 mcg with 120 doses.

Mylan President Rajiv Malik said, “Mylan is excited to be the first company to offer adult asthma patients in the UK the generic version of Seretide Evohaler, delivering on our mission to increase access to high quality medicine. Sirdupla represents a significant advancement for the company that both strengthens our respiratory portfolio and pipeline and further demonstrates our ability to successfully execute on one of our key strategic growth drivers.”

“3M will fill, assemble and package Sirdupla at 3M’s manufacturing facility in Loughborough, UK. By partnering with Mylan, 3M has taken an important step forward in the generics space. This partnership combines 3M’s expertise in inhalation drug development and manufacturing with Mylan’s leadership position in the global generics market, including expertise in commercializing complex respiratory products,” said Cindy Kent, president and general manager, Drug Delivery Systems.